Jessica Lynn has an educational background in writing and marketing. She firmly believes in the power of writing in amplifying voices, and looks forward to doing so for the rare disease community.

    LYNPARZA Trial for BRCA-Mutated HER2-Negative Breast Cancer Achieved iDFS Superiority Boundary
    Source: Pixabay

    LYNPARZA Trial for BRCA-Mutated HER2-Negative Breast Cancer Achieved iDFS Superiority Boundary

      In a joint statement, biopharmaceutical companies AstraZeneca and Merck & Co., Inc. ("Merck") shared that LYNPARZA (olaparib) achieved a superiority boundary in the Phase 3 OlympiA clinical trial. During…

    Continue Reading LYNPARZA Trial for BRCA-Mutated HER2-Negative Breast Cancer Achieved iDFS Superiority Boundary

    Updates Available on Givinostat Clinical Development for DMD

    During the virtual XVIII International Conference on Duchenne and Becker Muscular Dystrophy, specialty pharmaceutical company Italfarmaco Group ("Italfarmaco") shared updates regarding various Givinostat clinical development programs. The treatment is designed…

    Continue Reading Updates Available on Givinostat Clinical Development for DMD
    Five Genes Identified That May Cause Lewy Body Dementia
    source: pixabay.com

    Five Genes Identified That May Cause Lewy Body Dementia

    According to a recent press release, scientists studying the Uniformed Services University of the Health Sciences' (USU) The American Genome Center (TAGC) identified five genes which could play a role…

    Continue Reading Five Genes Identified That May Cause Lewy Body Dementia
    Discussing the New COVID-19 Variants
    source: pixabay.com

    Discussing the New COVID-19 Variants

    For nearly one year now, COVID-19 has dominated our headlines. In 2020, news emerged of SARS-CoV-2, a virus causing a global pandemic. Now, in February 2021, there are 110 million…

    Continue Reading Discussing the New COVID-19 Variants
    RSC-57 for Kabuki Syndrome Receives Orphan Drug and Rare Pediatric Disease Designations
    Free-Photos / Pixabay

    RSC-57 for Kabuki Syndrome Receives Orphan Drug and Rare Pediatric Disease Designations

    Just over a week ago, drug discovery and development company Rescindo Therapeutics Inc. ("Rescindo") shared that its drug candidate RSC-57 received both Orphan Drug and Rare Pediatric Disease designations. The…

    Continue Reading RSC-57 for Kabuki Syndrome Receives Orphan Drug and Rare Pediatric Disease Designations